A view from the Center

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Political fireworks of health reform may be nearing a crescendo

by Anne Phelps, Principal, US Health Care Regulatory Leader, Deloitte & Touche LLP

After seven years of political fireworks over the Affordable Care Act (ACA), a vote on the Senate’s bill to repeal and replace key elements of the law could be the prelude to a grand finale – or at least a crescendo – this week. On June 22, the Senate released the Better Care Reconciliation Act of 2017,

Read more

On the cusp of a tiny revolution – scientists work to overcome barriers to microscopic medicine

by Doug Beaudoin, Principal, Deloitte Consulting LLP

Many scientists are designing microscopic devices that can move through the body to diagnose conditions, carry drugs, or perform surgery. These devices are made of synthetic rods, tubes, helices, spheres or cages, sometimes as small as a cell. To date, these experiments are being studied in vitro, in conditions very different from the human body.

Read more

Cures, drug pricing, and collaboration are red-hot topics at summer life sciences conferences

by Greg Reh, Vice Chairman, US and Global Life Sciences Leader, Deloitte LLP

Two of the nation’s largest life sciences conferences are being held this week – and there definitely is no shortage of topics to dig into this year. The Biotechnology Innovation Organization’s (BIO) International Convention is taking place in San Diego, while the Drug Information Association’s (DIA) conference will be in Chicago. Several of my colleagues plan to share some of the industry’s latest thinking in sessions and meetings…and probably during informal coffee break chats,

Read more

Value-based contracting could help biopharma share drug costs, risks

by Ralph Marcello, Principal, Deloitte Consulting LLP

Drug pricing has been under a microscope for the past several years. It was on the platform during last year’s presidential election, and is a focus for the White House, Congress, and regulators. It seems only appropriate that we spend a little time discussing drug pricing at this year’s BIO International Convention.

Scientific progress is leading to effective but sometimes expensive treatments.

Read more

Precision Medicine Initiative takes another big step forward

by Doug Beaudoin, Principal, Deloitte Consulting LLP

This week, the National Institutes of Health (NIH) is moving forward with its Precision Medicine Initiative (PMI), through the launch of its All of Us Research Program. The program aims to collect information on lifestyle, the environment, and biometric data from 1 million Americans. PMI’s goal is to advance understanding of the underlying factors that influence health,

Read more

Curative therapies: Can breakthrough reimbursement models break through financial barriers?

by Tom Yang, Principal, Monitor Deloitte, Deloitte Consulting, LLP

For biopharma companies, it can be far more profitable to treat a disease than cure it. The traditional business model largely relies on the delivery of chronic therapies that slow disease progression and/or alleviate symptoms for patients with serious medical conditions. But the business model for curative therapeutics is different, and runs counter to this and many other industries where a successful product commonly leads to more customers and bigger profits.

Read more